National Jewish Medical and Research Center Selects QuadraMed's AFFINITY Enterprise Solution; AFFINITY Chosen for its Superior
Clinical Functionality
Business Wire - April 21, 1999 09:32
RICHMOND, Calif.--(BUSINESS WIRE)--April 21, 1999--QuadraMed Corporation (NASDAQ: QMDC) reported today that Colorado-based National Jewish Medical and Research Center -- a global leader in lung, allergic and immune diseases -- selected QuadraMed's AFFINITY healthcare information system (HIS). National Jewish chose AFFINITY for its reputation in the healthcare community as the leading system offering exceptional clinical and integrated patient financial systems.
Ranked by U.S. News and World Report in 1997 and 1988 as Best Hospital for Respiratory Care, National Jewish is a non-profit institution, founded in 1899, dedicated to enhancing prevention, treatment and cures through research, and innovative clinical treatment programs.
"As a leading medical center with 25 percent of our clinical faculty recognized in the second edition of The Best Doctors in America, it was our job to research every major vendor on the market," stated Verne Singleton, executive vice president and chief administrative officer at National Jewish Medical and Research Center. "After assessing all the products available, it was evident that AFFINITY would provide us with superior clinical functionality to better serve our patients."
The AFFINITY product line has been sought after by the healthcare community largely due to its open architecture, flexibility, ease-of-use and exceptional functionality. QuadraMed's robust AFFINITY HIS is Web-enabled, providing users with online and real-time access to information -- a feature that continues to gain importance in the delivery of high-quality, cost-effective healthcare.
"We are pleased that the renowned National Jewish Medical and Research Center has selected AFFINITY as their healthcare information system of choice," stated Nancy Nelson, leader of QuadraMed's enterprise division. "Clearly, this is an exciting win for us but more importantly, it's a validation that we are on track with our commitment to provide the best possible healthcare tools for clinicians."
About QuadraMed Corporation
QuadraMed Corporation uses technology to transform disparate healthcare data into valuable, enterprise-wide information. Providing and distributing meaningful information through its software, services and Internet solutions, QuadraMed has enabled its 3,800 customers in the U.S. and Canada to generate operational efficiencies, improve cash flow and measure the cost and quality of care. QuadraMed has implemented its product and service solutions in more than 60% of the nation's hospitals. For more information about AFFINITY, please call 800/207-0983, ext. 800 or visit our Web sites at www.CompucareOnline.com or www.Quadramed.com.
AffinitySTAT is a trademark of QuadraMed Corporation. All other trademarks and registered trademarks are the properties of their respective holders.
Except for the historical financial information contained herein, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties; actual results could differ materially from those indicated by such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: (i) variability in quarterly operating results, (ii) identification, consummation and assimilation of acquisitions, (iii) dependence on large orders and customer concentration, (iv) dependence on hospitals and demand for the Company products and services in the healthcare information systems and services markets, (v) legislative or market-driven reforms in the healthcare industry, (vi) the Company's ability to develop and introduce new products, (vii) management of the Company's changing operations, (viii) dependence on key personnel, (ix) development by competitors of new or superior products or entry into the market of new competitors, (x) risks related to product defects, (xi) risks associated with pending litigation, (xii) dependence on intellectual property rights, (xiii) volatility in the Company's stock price and historically low trading volume, (xiv) the success or failure of strategic alliances, (xv) risk of interruption in data processing, (xvi) risks associated with certain investments in early stage companies, and (xvii) other risks identified from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission, including the Annual Report on Form 10-K filed on March 31, 1999.
CONTACT: QuadraMed Corporation
James D. Durham, 510/620-2340 (Chairman and CEO)
John V. Cracchiolo, 510/620-2340 (President and COO)
Stacey Levitz, 510/620-2340 (Director of IR)
www.quadramed.com |
